Head-to-head · WeighScore
TeleFirst Med vs Willow
The verdict
Willow takes it — 58.2/100 to 57.4/100, but only just.
Willow grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider offering compounded GLP-1 medications in both tablet and injectable formats. TeleFirst Med is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | TeleFirst Med | Willow |
|---|---|---|
| WeighScore | 57.4/100 | 58.2/100 |
| Grade | C | C |
| Scorecard rank | #400 | #377 |
| Semaglutide | Not disclosed | $299/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $399/mo (starting dose, compounded) |
| Coverage | 2 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #400 · C
Strengths
- Prescribes real brand-name GLP-1 (e.g. Ozempic/Wegovy), not compounded — appealing if you specifically want FDA-approved branded medication
- Simple $120 telehealth evaluation with a licensed doctor; no insurance hassle and no prior authorization
- You fill the prescription at your own regular pharmacy rather than waiting on a mail-order compounding pharmacy
- Also a general telehealth clinic (urgent care, chronic-condition management) if you want broader care
Where it loses points
- Only Texas and North Carolina are confirmed — not available nationwide
- The $120 is an evaluation fee; the brand-name medication is billed separately at your pharmacy and can be expensive without insurance
- Small practice (about 500 patients) with limited public detail on its clinicians and program
- No compounded or lower-cost medication option, and no medication pricing is published
Graded #377 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.